Novo regained weight loss footing in the pill arena — but Lilly is coming

Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?

By Alivia Kaylor • March 13, 2026

Keytruda’s reign continues; pharma’s megadeal drought

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.

By PharmaVoice Staff • March 13, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Keytruda and Padcev could become cancer’s power couple

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

By Alexandra Pecci • March 11, 2026

Executives want in, but researchers want out — how pharma’s US job picture is changing

While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.

By Alexandra Pecci • March 10, 2026

The first KRAS drugs have been sluggish on the market. Will the next generation fare better?

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

By Kelly Bilodeau • March 9, 2026

Cancer tests are becoming more precise and guiding pharma R&D

Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D. 

By Michael Gibney • March 5, 2026

What 3 recent FDA rejections reveal about shifts inside the agency

The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.

By Alexandra Pecci • March 4, 2026

Inside the race to thwart the dramatic rise in early-onset colorectal cancer

The increasingly common disease still presents a major challenge in oncology.

By Kelly Bilodeau • March 4, 2026

J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

Spravato became a blockbuster despite ketamine’s dangerous abuse history, causing doctors to balance the real-world implications of its use.

By Michael Gibney • March 3, 2026

How does the FDA really feel about psychedelics? We could soon find out.

Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.

By Kelly Bilodeau • Feb. 23, 2026

No one-trick pony in oncology, Merck’s cancer footprint is expanding

The three key therapeutic approaches Merck is leveraging to craft its next era in cancer care.

By Meagan Parrish • Feb. 20, 2026

Pharma could be on the cusp of finally breaking the blood-brain barrier

Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground. 

By Kelly Bilodeau • Feb. 18, 2026

More drugmakers are turning to cancer combos. Will it help patients live longer?

Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.

By Kelly Bilodeau • Feb. 17, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.

By Michael Gibney • Feb. 12, 2026

A protein model designed for space could expand pharma’s definition of ‘druggability’

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.

By Michael Gibney • Feb. 11, 2026

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

By Alexandra Pecci • Feb. 10, 2026

New FDA guidance that’s a ‘huge deal’ for clinical trials

Why using Bayesian statistics could transform trial design for rare diseases and beyond.

By Kelly Bilodeau • Feb. 10, 2026

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.

By Kelly Bilodeau • Feb. 9, 2026

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

By Meagan Parrish • Feb. 6, 2026

Big Pharma CEOs set sights on massive growth in years to come

The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.

By Michael Gibney • Feb. 5, 2026

The most valuable up-and-coming GLP-1s

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

By Alivia Kaylor • Feb. 5, 2026

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.

By Michael Gibney • Feb. 3, 2026

Mirum doubles down on diversified rare disease strategy

With the purchase of biotech Bluejay, Mirum stays focused on building a company with a broad pipeline and portfolio devoted to rare diseases.

By Alexandra Pecci • Feb. 3, 2026

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

By Meagan Parrish • Jan. 30, 2026